The focus on distribution signifies that CD19 remains the central axis of innovation, but the sector is actively diversifying. An important preclinical and early scientific thrust aims to mitigate antigen escape by way of dual-focusing on or multi-concentrating on types.The trade-off is authentic: about a fifth of clients will not respond at all, a